45 Horsehill Road, Suite 106, Cedar Knolls, NJ 07927
(973) 509-0444
Follow us

HomeKansas State University Canine Clinical Study

Do you have a furry friend at home that has lost muscle mass?  If so, go to www.myospet.com where you can learn more about our revolutionary all natural, advanced nutrition product, MYOS Canine Muscle Formula® that has been shown in a clinical study to reduce muscle atrophy following surgery.

Kansas State University Canine Clinical Trial

A randomized, double-blind, placebo-controlled study was performed at Kansas State University to evaluate the impact of Fortetropin on muscle atrophy in 100 dogs after TPLO surgery (similar to ACL surgery in humans to repair torn ligament). The key findings of this clinical study were:

Pet Nutrition

  • Fortetropin® prevented the loss of muscle mass in the affected and unaffected limbs.
  • Fortetropin-supplemented dogs had a more significant improvement in percentage of weight supported by the affected limb.
  • Fortetropin prevented a rise in serum myostatin levels (myostatin is a protein that prevents muscle growth.)

Reference:

White, Dana A., et al. “Fortetropin inhibits disuse muscle atrophy in dogs after tibial plateau leveling osteotomy.” Plos one 15.4 (2020): e0231306.

Ongoing Canine Clinical Trials

  • A randomized, double-blind, placebo-controlled study is underway at Kansas State University to evaluate the impact of Fortetropin on quality of life and mobility in geriatric dogs.
  • A randomized, double-blind, placebo-controlled crossover study is underway at Animal Medical Center, New York to evaluate the impact of Fortetropin on serum myostatin levels in dogs over the course of 24 hours.

MYOS CORP is an emerging company focused on improving muscle health through the development of advanced nutrition products.

Contact Us

CORPORATE HEADQUARTERS

Morris Technical Center
45 Horsehill Road, Suite 106
Cedar Knolls, NJ 07927
(973) 509-0444
info@myoscorp.com

SOCIAL & NEWSLETTER

Sign up for
our newsletter

Invalid or empty email
You have successfully subscribed to the newsletter.
Something went wrong. Your subscription failed.

Follow us